ATE353638T1 - Verwendung von nf-kappa b hemmern zur behandlung von brustdrüsenentzündung - Google Patents

Verwendung von nf-kappa b hemmern zur behandlung von brustdrüsenentzündung

Info

Publication number
ATE353638T1
ATE353638T1 AT03753579T AT03753579T ATE353638T1 AT E353638 T1 ATE353638 T1 AT E353638T1 AT 03753579 T AT03753579 T AT 03753579T AT 03753579 T AT03753579 T AT 03753579T AT E353638 T1 ATE353638 T1 AT E353638T1
Authority
AT
Austria
Prior art keywords
kappa
inhibitors
treatment
mammary inflammation
mammary
Prior art date
Application number
AT03753579T
Other languages
English (en)
Inventor
Delphine Boulanger
Fabrice Bureau
Pierre Lekeux
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE353638T1 publication Critical patent/ATE353638T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT03753579T 2002-08-14 2003-08-12 Verwendung von nf-kappa b hemmern zur behandlung von brustdrüsenentzündung ATE353638T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02078352 2002-08-14

Publications (1)

Publication Number Publication Date
ATE353638T1 true ATE353638T1 (de) 2007-03-15

Family

ID=31725450

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03753579T ATE353638T1 (de) 2002-08-14 2003-08-12 Verwendung von nf-kappa b hemmern zur behandlung von brustdrüsenentzündung

Country Status (10)

Country Link
US (1) US20060240011A1 (de)
EP (1) EP1536777B1 (de)
JP (1) JP2005539028A (de)
AT (1) ATE353638T1 (de)
AU (1) AU2003271747B2 (de)
CA (1) CA2495068A1 (de)
DE (1) DE60311825T2 (de)
DK (1) DK1536777T3 (de)
ES (1) ES2282658T3 (de)
WO (1) WO2004016253A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004021281A1 (de) * 2004-04-29 2005-11-24 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin
WO2015000022A1 (en) * 2013-07-05 2015-01-08 Adelaide Research & Innovation Pty Ltd Treatment and prevention of mastitis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
NZ514522A (en) * 1999-03-22 2004-03-26 Charterhouse Therapeutics Ltd Chemical compounds and their uses
GB9922505D0 (en) * 1999-09-24 1999-11-24 Kennedy Rheumatology Inst Therapeutic methods and compounds

Also Published As

Publication number Publication date
EP1536777A1 (de) 2005-06-08
US20060240011A1 (en) 2006-10-26
DE60311825D1 (de) 2007-03-29
CA2495068A1 (en) 2004-02-26
JP2005539028A (ja) 2005-12-22
DE60311825T2 (de) 2007-12-06
EP1536777B1 (de) 2007-02-14
AU2003271747A1 (en) 2004-03-03
DK1536777T3 (da) 2007-06-04
WO2004016253A1 (en) 2004-02-26
AU2003271747B2 (en) 2008-09-11
ES2282658T3 (es) 2007-10-16

Similar Documents

Publication Publication Date Title
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DK1651161T3 (da) Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
EE200400020A (et) Asendatud oksasolidinoonid kombineeritud raviks
NO20063064L (no) Ny anvendelse av peptidforbindelser for behandling av sentralneurotisk smerte
SE0301888D0 (sv) New use VII
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
DE60312969D1 (de) Zubereitung für die wundheilung und zur verhinderung des anhaftens von verbänden an die wunde
DE60328603D1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
ATE443044T1 (de) Tace inhibitoren
ATE290384T1 (de) Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
HUP0204551A2 (hu) Eljárás a pikkelysömör kezelésére
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
SE0002739D0 (sv) New use
ATE353638T1 (de) Verwendung von nf-kappa b hemmern zur behandlung von brustdrüsenentzündung
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
SE0301883D0 (sv) New use II
ATE392212T1 (de) Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen
ATE453386T1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
SE0301885D0 (sv) New use IV
SE0301884D0 (sv) New use III
DE60330233D1 (de) Arsentherapie zur behandlung von autoimmunerkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties